TY - JOUR AU - Shellenberger, R. AU - Nabhan, M. AU - Kakaraparthi, S. PY - 2016 DA - 2016// TI - Melanoma screening: a plan for improving early detection JO - Ann Med VL - 48 UR - https://doi.org/10.3109/07853890.2016.1145795 DO - 10.3109/07853890.2016.1145795 ID - Shellenberger2016 ER - TY - BOOK PY - 2017 DA - 2017// TI - SEER Cancer Statistics Review, 1975-2014 PB - National Cancer Institute CY - Bethesda ID - ref2 ER - TY - JOUR AU - Rozeman, E. l. i. s. a. A. AU - Dekker, T. i. m. J. A. AU - Haanen, J. o. h. n. B. A. G. AU - Blank, C. h. r. i. s. t. i. a. n. U. PY - 2017 DA - 2017// TI - Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives JO - American Journal of Clinical Dermatology VL - 19 UR - https://doi.org/10.1007/s40257-017-0325-6 DO - 10.1007/s40257-017-0325-6 ID - Rozeman2017 ER - TY - JOUR AU - Eggermont, A. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2015 DA - 2015// TI - Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70122-1 DO - 10.1016/S1470-2045(15)70122-1 ID - Eggermont2015 ER - TY - JOUR AU - Vermaelen, K. AU - Waeytens, A. AU - Kholmanskikh, O. AU - Van den Bulcke, M. AU - Van Valckenborgh, E. PY - 2018 DA - 2018// TI - Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting JO - Seminars in Cancer Biology VL - 52 UR - https://doi.org/10.1016/j.semcancer.2017.11.011 DO - 10.1016/j.semcancer.2017.11.011 ID - Vermaelen2018 ER - TY - JOUR AU - Schachter, J. AU - Ribas, A. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2017 DA - 2017// TI - Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31601-X DO - 10.1016/S0140-6736(17)31601-X ID - Schachter2017 ER - TY - JOUR AU - Keller, H. R. AU - Zhang, X. AU - Li, L. AU - Schaider, H. AU - Wells, J. W. PY - 2017 DA - 2017// TI - Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.18523 DO - 10.18632/oncotarget.18523 ID - Keller2017 ER - TY - JOUR AU - Ashburn, T. T. AU - Thor, K. B. PY - 2004 DA - 2004// TI - Drug repositioning: identifying and developing new uses for existing drugs JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1468 DO - 10.1038/nrd1468 ID - Ashburn2004 ER - TY - JOUR AU - Lee, H. J. AU - Park, M. K. AU - Kim, S. Y. AU - Park Choo, H. Y. AU - Lee, A. Y. AU - Lee, C. H. PY - 2011 DA - 2011// TI - Serotonin induces melanogenesis via serotonin receptor 2A JO - Br J Dermatol VL - 165 UR - https://doi.org/10.1111/j.1365-2133.2011.10490.x DO - 10.1111/j.1365-2133.2011.10490.x ID - Lee2011 ER - TY - JOUR AU - Weidmann, C. AU - Berube, J. AU - Piquet, L. AU - Fouchardiere, A. AU - Landreville, S. PY - 2018 DA - 2018// TI - Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines JO - Clin Exp Metastasis VL - 35 UR - https://doi.org/10.1007/s10585-018-9894-x DO - 10.1007/s10585-018-9894-x ID - Weidmann2018 ER - TY - JOUR AU - Uzawa, K. AU - Kasamatsu, A. AU - Shimizu, T. AU - Saito, Y. AU - Baba, T. AU - Sakuma, K. PY - 2014 DA - 2014// TI - Suppression of metastasis by mirtazapine via restoration of the Lin-7C/beta-catenin pathway in human cancer cells JO - Sci Rep VL - 4 UR - https://doi.org/10.1038/srep05433 DO - 10.1038/srep05433 ID - Uzawa2014 ER - TY - JOUR AU - Minden, M. D. AU - Dimitroulakos, J. AU - Nohynek, D. AU - Penn, L. Z. PY - 2001 DA - 2001// TI - Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia JO - Leuk Lymphoma VL - 40 UR - https://doi.org/10.3109/10428190109097663 DO - 10.3109/10428190109097663 ID - Minden2001 ER - TY - JOUR AU - Spagnuolo, P. A. AU - Hu, J. AU - Hurren, R. AU - Wang, X. AU - Gronda, M. AU - Sukhai, M. A. PY - 2010 DA - 2010// TI - The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-09-243055 DO - 10.1182/blood-2009-09-243055 ID - Spagnuolo2010 ER - TY - JOUR AU - Liang, G. AU - Liu, M. AU - Wang, Q. AU - Shen, Y. AU - Mei, H. AU - Li, D. PY - 2017 DA - 2017// TI - Itraconazole exerts its anti-melanoma effect by suppressing hedgehog, Wnt, and PI3K/mTOR signaling pathways JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.15324 DO - 10.18632/oncotarget.15324 ID - Liang2017 ER - TY - JOUR AU - Cameron, D. AU - Morden, J. P. AU - Canney, P. AU - Velikova, G. AU - Coleman, R. AU - Bartlett, J. PY - 2017 DA - 2017// TI - Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30404-7 DO - 10.1016/S1470-2045(17)30404-7 ID - Cameron2017 ER - TY - JOUR AU - Barretina, J. AU - Caponigro, G. AU - Stransky, N. AU - Venkatesan, K. AU - Margolin, A. A. AU - Kim, S. PY - 2012 DA - 2012// TI - The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11003 DO - 10.1038/nature11003 ID - Barretina2012 ER - TY - JOUR AU - Mikami, T. AU - Sugimoto, H. AU - Naganeo, R. AU - Ohmi, T. AU - Saito, T. AU - Eda, H. PY - 2008 DA - 2008// TI - Contribution of active and inactive states of the human 5-HT4d receptor to the functional activities of 5-HT4-receptor agonists JO - J Pharmacol Sci VL - 107 UR - https://doi.org/10.1254/jphs.FP0072230 DO - 10.1254/jphs.FP0072230 ID - Mikami2008 ER - TY - JOUR AU - Nichols, D. E. AU - Nichols, C. D. PY - 2008 DA - 2008// TI - Serotonin receptors JO - Chem Rev VL - 108 UR - https://doi.org/10.1021/cr078224o DO - 10.1021/cr078224o ID - Nichols2008 ER - TY - JOUR AU - Dominguez-Soto, A. AU - Usategui, A. AU - Casas-Engel, M. L. AU - Simon-Fuentes, M. AU - Nieto, C. AU - Cuevas, V. D. PY - 2017 DA - 2017// TI - Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-15348-y DO - 10.1038/s41598-017-15348-y ID - Dominguez-Soto2017 ER - TY - JOUR AU - Paluncic, J. AU - Kovacevic, Z. AU - Jansson, P. J. AU - Kalinowski, D. AU - Merlot, A. M. AU - Huang, M. L. PY - 2016 DA - 2016// TI - Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling JO - Biochim Biophys Acta VL - 1863 UR - https://doi.org/10.1016/j.bbamcr.2016.01.025 DO - 10.1016/j.bbamcr.2016.01.025 ID - Paluncic2016 ER - TY - JOUR AU - Burnett, P. E. AU - Barrow, R. K. AU - Cohen, N. A. AU - Snyder, S. H. AU - Sabatini, D. M. PY - 1998 DA - 1998// TI - RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 JO - Proc Natl Acad Sci U S A VL - 95 UR - https://doi.org/10.1073/pnas.95.4.1432 DO - 10.1073/pnas.95.4.1432 ID - Burnett1998 ER - TY - JOUR AU - Roux, P. P. AU - Shahbazian, D. AU - Vu, H. AU - Holz, M. K. AU - Cohen, M. S. AU - Taunton, J. PY - 2007 DA - 2007// TI - RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation JO - J Biol Chem VL - 282 UR - https://doi.org/10.1074/jbc.M700906200 DO - 10.1074/jbc.M700906200 ID - Roux2007 ER - TY - JOUR AU - Corcoran, R. B. AU - Rothenberg, S. M. AU - Hata, A. N. AU - Faber, A. C. AU - Piris, A. AU - Nazarian, R. M. PY - 2013 DA - 2013// TI - TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3005753 DO - 10.1126/scitranslmed.3005753 ID - Corcoran2013 ER - TY - JOUR AU - Kleffel, S. AU - Posch, C. AU - Barthel, S. R. AU - Mueller, H. AU - Schlapbach, C. AU - Guenova, E. PY - 2015 DA - 2015// TI - Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth JO - Cell VL - 162 UR - https://doi.org/10.1016/j.cell.2015.08.052 DO - 10.1016/j.cell.2015.08.052 ID - Kleffel2015 ER - TY - JOUR AU - Manning, B. D. AU - Tee, A. R. AU - Logsdon, M. N. AU - Blenis, J. AU - Cantley, L. C. PY - 2002 DA - 2002// TI - Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway JO - Mol Cell VL - 10 UR - https://doi.org/10.1016/S1097-2765(02)00568-3 DO - 10.1016/S1097-2765(02)00568-3 ID - Manning2002 ER - TY - JOUR AU - Meyuhas, O. PY - 2015 DA - 2015// TI - Ribosomal protein S6 phosphorylation: four decades of research JO - Int Rev Cell Mol Biol VL - 320 UR - https://doi.org/10.1016/bs.ircmb.2015.07.006 DO - 10.1016/bs.ircmb.2015.07.006 ID - Meyuhas2015 ER - TY - JOUR AU - Sarbassov, D. D. AU - Guertin, D. A. AU - Ali, S. M. AU - Sabatini, D. M. PY - 2005 DA - 2005// TI - Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex JO - Science (New York, N Y ) VL - 307 UR - https://doi.org/10.1126/science.1106148 DO - 10.1126/science.1106148 ID - Sarbassov2005 ER - TY - JOUR AU - Feng, J. AU - Park, J. AU - Cron, P. AU - Hess, D. AU - Hemmings, B. A. PY - 2004 DA - 2004// TI - Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M406731200 DO - 10.1074/jbc.M406731200 ID - Feng2004 ER - TY - JOUR AU - Yoon, S. -. O. AU - Shin, S. AU - Karreth, F. A. AU - Buel, G. R. AU - Jedrychowski, M. P. AU - Plas, D. R. PY - 2017 DA - 2017// TI - Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition JO - Mol Cell VL - 67 UR - https://doi.org/10.1016/j.molcel.2017.06.033 DO - 10.1016/j.molcel.2017.06.033 ID - Yoon2017 ER - TY - JOUR AU - Maira, G. AU - Salvi, M. AU - Arrigoni, G. AU - Marin, O. AU - Sarno, S. AU - Brustolon, F. PY - 2005 DA - 2005// TI - Protein kinase CK2 phosphorylates and upregulates Akt/PKB JO - Cell Death Differ VL - 12 UR - https://doi.org/10.1038/sj.cdd.4401604 DO - 10.1038/sj.cdd.4401604 ID - Maira2005 ER - TY - JOUR AU - Gulen, M. F. AU - Bulek, K. AU - Xiao, H. AU - Yu, M. AU - Gao, J. AU - Sun, L. PY - 2012 DA - 2012// TI - Inactivation of the enzyme GSK3alpha by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance JO - Immunity VL - 37 UR - https://doi.org/10.1016/j.immuni.2012.08.019 DO - 10.1016/j.immuni.2012.08.019 ID - Gulen2012 ER - TY - JOUR AU - Varghese, F. AU - Bukhari, A. B. AU - Malhotra, R. AU - De, A. PY - 2014 DA - 2014// TI - IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0096801 DO - 10.1371/journal.pone.0096801 ID - Varghese2014 ER - TY - JOUR AU - Ohue, Y. AU - Nishikawa, H. PY - 2019 DA - 2019// TI - Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? JO - Cancer Sci VL - 110 UR - https://doi.org/10.1111/cas.14069 DO - 10.1111/cas.14069 ID - Ohue2019 ER - TY - JOUR AU - Ali, K. AU - Soond, D. R. AU - Pineiro, R. AU - Hagemann, T. AU - Pearce, W. AU - Lim, E. L. PY - 2014 DA - 2014// TI - Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer JO - Nature VL - 510 UR - https://doi.org/10.1038/nature13444 DO - 10.1038/nature13444 ID - Ali2014 ER - TY - JOUR AU - Larkin, J. AU - Vecchio, M. AU - Ascierto, P. A. AU - Krajsova, I. AU - Schachter, J. AU - Neyns, B. PY - 2014 DA - 2014// TI - Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70051-8 DO - 10.1016/S1470-2045(14)70051-8 ID - Larkin2014 ER - TY - JOUR AU - Berger, M. AU - Gray, J. A. AU - Roth, B. L. PY - 2009 DA - 2009// TI - The expanded biology of serotonin JO - Annu Rev Med VL - 60 UR - https://doi.org/10.1146/annurev.med.60.042307.110802 DO - 10.1146/annurev.med.60.042307.110802 ID - Berger2009 ER - TY - JOUR AU - Jiang, S. H. AU - Li, J. AU - Dong, F. Y. AU - Yang, J. Y. AU - Liu, D. J. AU - Yang, X. M. PY - 2017 DA - 2017// TI - Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice JO - Gastroenterology VL - 153 UR - https://doi.org/10.1053/j.gastro.2017.03.008 DO - 10.1053/j.gastro.2017.03.008 ID - Jiang2017 ER - TY - JOUR AU - Sarrouilhe, D. AU - Clarhaut, J. AU - Defamie, N. AU - Mesnil, M. PY - 2015 DA - 2015// TI - Serotonin and cancer: what is the link? JO - Curr Mol Med VL - 15 UR - https://doi.org/10.2174/1566524015666150114113411 DO - 10.2174/1566524015666150114113411 ID - Sarrouilhe2015 ER - TY - JOUR AU - Etxabe, A. AU - Lara-Castillo, M. C. AU - Cornet-Masana, J. M. AU - Banus-Mulet, A. AU - Nomdedeu, M. AU - Torrente, M. A. PY - 2017 DA - 2017// TI - Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.52 DO - 10.1038/leu.2017.52 ID - Etxabe2017 ER - TY - JOUR AU - Pollard, S. M. AU - Yoshikawa, K. AU - Clarke, I. D. AU - Danovi, D. AU - Stricker, S. AU - Russell, R. PY - 2009 DA - 2009// TI - Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens JO - Cell Stem Cell VL - 4 UR - https://doi.org/10.1016/j.stem.2009.03.014 DO - 10.1016/j.stem.2009.03.014 ID - Pollard2009 ER - TY - JOUR AU - Jose, J. AU - Tavares, C. D. J. AU - Ebelt, N. D. AU - Lodi, A. AU - Edupuganti, R. AU - Xie, X. PY - 2017 DA - 2017// TI - Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth JO - Med Chem Lett VL - 8 UR - https://doi.org/10.1021/acsmedchemlett.7b00282 DO - 10.1021/acsmedchemlett.7b00282 ID - Jose2017 ER - TY - JOUR AU - Maeyer, J. H. AU - Lefebvre, R. A. AU - Schuurkes, J. A. PY - 2008 DA - 2008// TI - 5-HT4 receptor agonists: similar but not the same JO - Neurogastroenterol Motil VL - 20 UR - https://doi.org/10.1111/j.1365-2982.2007.01059.x DO - 10.1111/j.1365-2982.2007.01059.x ID - Maeyer2008 ER - TY - JOUR AU - Beattie, D. T. AU - Smith, J. A. AU - Marquess, D. AU - Vickery, R. G. AU - Armstrong, S. R. AU - Pulido-Rios, T. PY - 2004 DA - 2004// TI - The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo JO - Br J Pharmacol VL - 143 UR - https://doi.org/10.1038/sj.bjp.0705929 DO - 10.1038/sj.bjp.0705929 ID - Beattie2004 ER - TY - JOUR AU - Mattia, G. AU - Puglisi, R. AU - Ascione, B. AU - Malorni, W. AU - Care, A. AU - Matarrese, P. PY - 2018 DA - 2018// TI - Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies JO - Cell Death Dis VL - 9 UR - https://doi.org/10.1038/s41419-017-0059-7 DO - 10.1038/s41419-017-0059-7 ID - Mattia2018 ER - TY - JOUR AU - Joseph, E. W. AU - Pratilas, C. A. AU - Poulikakos, P. I. AU - Tadi, M. AU - Wang, W. AU - Taylor, B. S. PY - 2010 DA - 2010// TI - The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1008990107 DO - 10.1073/pnas.1008990107 ID - Joseph2010 ER - TY - JOUR AU - Broussard, L. AU - Howland, A. AU - Ryu, S. AU - Song, K. AU - Norris, D. AU - Armstrong, C. A. PY - 2018 DA - 2018// TI - Melanoma cell death mechanisms JO - Chonnam Med J VL - 54 UR - https://doi.org/10.4068/cmj.2018.54.3.135 DO - 10.4068/cmj.2018.54.3.135 ID - Broussard2018 ER - TY - JOUR AU - Torres-Collado, A. n. t. o. n. i. AU - Knott, J. e. f. f. r. e. y. AU - Jazirehi, A. l. i. PY - 2018 DA - 2018// TI - Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor) JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10060157 DO - 10.3390/cancers10060157 ID - Torres-Collado2018 ER - TY - JOUR AU - Posch, C. AU - Moslehi, H. AU - Feeney, L. AU - Green, G. A. AU - Ebaee, A. AU - Feichtenschlager, V. PY - 2013 DA - 2013// TI - Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1216013110 DO - 10.1073/pnas.1216013110 ID - Posch2013 ER - TY - JOUR AU - Inoki, K. AU - Ouyang, H. AU - Zhu, T. AU - Lindvall, C. AU - Wang, Y. AU - Zhang, X. PY - 2006 DA - 2006// TI - TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth JO - Cell VL - 126 UR - https://doi.org/10.1016/j.cell.2006.06.055 DO - 10.1016/j.cell.2006.06.055 ID - Inoki2006 ER - TY - JOUR AU - Togashi, Y. AU - Shitara, K. AU - Nishikawa, H. PY - 2019 DA - 2019// TI - Regulatory T cells in cancer immunosuppression - implications for anticancer therapy JO - Nat Rev Clin Oncol VL - 16 UR - https://doi.org/10.1038/s41571-019-0175-7 DO - 10.1038/s41571-019-0175-7 ID - Togashi2019 ER - TY - JOUR AU - Muller-Lissner, S. A. AU - Fumagalli, I. AU - Bardhan, K. D. AU - Pace, F. AU - Pecher, E. AU - Nault, B. PY - 2001 DA - 2001// TI - Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation JO - Aliment Pharmacol Ther VL - 15 UR - https://doi.org/10.1046/j.1365-2036.2001.01094.x DO - 10.1046/j.1365-2036.2001.01094.x ID - Muller-Lissner2001 ER - TY - JOUR AU - Nyhlin, H. AU - Bang, C. AU - Elsborg, L. AU - Silvennoinen, J. AU - Holme, I. AU - Ruegg, P. PY - 2004 DA - 2004// TI - A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome JO - Scand J Gastroenterol VL - 39 UR - https://doi.org/10.1080/00365520310006748 DO - 10.1080/00365520310006748 ID - Nyhlin2004 ER - TY - JOUR AU - Johanson, J. F. AU - Wald, A. AU - Tougas, G. AU - Chey, W. D. AU - Novick, J. S. AU - Lembo, A. J. PY - 2004 DA - 2004// TI - Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial JO - Clin Gastroenterol Hepatol VL - 2 UR - https://doi.org/10.1016/S1542-3565(04)00356-8 DO - 10.1016/S1542-3565(04)00356-8 ID - Johanson2004 ER - TY - JOUR AU - Thompson, C. A. PY - 2007 DA - 2007// TI - Novartis suspends tegaserod sales at FDA's request JO - Am J Health Syst Pharm VL - 64 UR - https://doi.org/10.2146/news070044 DO - 10.2146/news070044 ID - Thompson2007 ER - TY - JOUR AU - Anderson, J. L. AU - May, H. T. AU - Bair, T. L. AU - Muhlestein, J. B. AU - Horne, B. D. AU - Carlquist, J. F. PY - 2009 DA - 2009// TI - Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study JO - J Cardiovasc Pharmacol Ther VL - 14 UR - https://doi.org/10.1177/1074248409340158 DO - 10.1177/1074248409340158 ID - Anderson2009 ER - TY - JOUR AU - Loughlin, J. AU - Quinn, S. AU - Rivero, E. AU - Wong, J. AU - Huang, J. AU - Kralstein, J. PY - 2010 DA - 2010// TI - Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study JO - J Cardiovasc Pharmacol Ther VL - 15 UR - https://doi.org/10.1177/1074248409360357 DO - 10.1177/1074248409360357 ID - Loughlin2010 ER - TY - JOUR AU - Nair, A. B. AU - Jacob, S. PY - 2016 DA - 2016// TI - A simple practice guide for dose conversion between animals and human JO - J Basic Clin Pharm VL - 7 UR - https://doi.org/10.4103/0976-0105.177703 DO - 10.4103/0976-0105.177703 ID - Nair2016 ER - TY - JOUR AU - Johnpulle, R. A. N. AU - Johnson, D. B. AU - Sosman, J. A. PY - 2016 DA - 2016// TI - Molecular targeted therapy approaches for BRAF wild-type melanoma JO - Curr Oncol Rep VL - 18 UR - https://doi.org/10.1007/s11912-015-0485-6 DO - 10.1007/s11912-015-0485-6 ID - Johnpulle2016 ER - TY - JOUR AU - Larkin, J. AU - Lao, C. D. AU - Urba, W. J. AU - McDermott, D. F. AU - Horak, C. AU - Jiang, J. PY - 2015 DA - 2015// TI - Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials JO - JAMA Oncol VL - 1 UR - https://doi.org/10.1001/jamaoncol.2015.1184 DO - 10.1001/jamaoncol.2015.1184 ID - Larkin2015 ER - TY - JOUR AU - Chou, T. C. AU - Talalay, P. PY - 1984 DA - 1984// TI - Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors JO - Adv Enzym Regul VL - 22 UR - https://doi.org/10.1016/0065-2571(84)90007-4 DO - 10.1016/0065-2571(84)90007-4 ID - Chou1984 ER - TY - JOUR AU - Goldman, M. AU - Craft, B. AU - Swatloski, T. AU - Cline, M. AU - Morozova, O. AU - Diekhans, M. PY - 2015 DA - 2015// TI - The UCSC Cancer genomics browser: update 2015 JO - Nucleic Acids Res VL - 43 UR - https://doi.org/10.1093/nar/gku1073 DO - 10.1093/nar/gku1073 ID - Goldman2015 ER -